[Federal Register Volume 85, Number 56 (Monday, March 23, 2020)]
[Notices]
[Pages 16368-16369]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06082]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-N-0008]
Blood Products Advisory Committee; Postponed
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Blood Products Advisory Committee (BPAC)
scheduled for April 2-3, 2020, is postponed. The Food and Drug
Administration (FDA), like other government agencies, is taking the
necessary steps to ensure the Agency is prepared to continue our vital
public health mission in the event that our day-to-day operations are
impacted by the
[[Page 16369]]
COVID-19 public health emergency. Therefore, we are canceling or
postponing all non-essential meetings through the month of April. We
will reassess on an ongoing basis for future months. Therefore, this
meeting is being postponed. The meeting was announced in the Federal
Register on February 13, 2020.
FOR FURTHER INFORMATION CONTACT: Christina Vert, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 6268, Silver Spring, MD 20993-0002, 240-
402-8054, [email protected], or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), and follow the prompts to the desired center or product area.
Please call the Information Line for up-to-date information on this
meeting, which was announced in the Federal Register of February 13,
2020, 85 FR 8299.
Dated: March 18, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-06082 Filed 3-20-20; 8:45 am]
BILLING CODE 4164-01-P